Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study is a single-blind randomized controlled dose-ranging trial aiming at providing
evidence on the on the optimal dose of co-administered ivermectin and albendazole in terms of
efficacy, safety and acceptability in preschool-aged children (PSAC; aged 2-5 years) infected
with whipworm (Trichuris trichiura) on Pemba Island, Tanzania. Additionally, the
pharmacokinetics of the newly developed ODTs and the standard ivermectin tablets
(Stromectol®) will be compared in this age group.
As measure of efficacy of the treatment the cure rate (percentage of egg-positive
participants at baseline who become egg-negative after treatment) will be determined 14-21
days post-treatment.